Kathleen Kelley
Optometrist · Indianapolis, INNPI 1588646566
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,208 of the $3,133 with a category attached, or 70.5%. 23 manufacturers reported payments, led by Lensar, Inc. at 40.6% of the total. Reporting peaked in 2021 at $1,488 and has fallen 57.7% since, to $630 in 2025.
Across 60 payments — averaging $52.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lensar, Inc.$1K
- Bausch & Lomb Americas Inc.$982
- Novartis$113
- AbbVie$105
- Ocular Therapeutix, Inc.$96
- Harrow Eye, LLC$72
- plus $494 from 17 others
Across 30 payments — averaging $6232.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Oyster Point Pharma, Inc.$89K
- Bausch Health US, LLC$47K
- Ocular Therapeutix, Inc.$27K
- AbbVie$13K
- Kala Pharmaceuticals, Inc.$12K
What the payments were for
- Consulting fees$502%
- Speaking & faculty fees$87528%
- Food & beverage$2,20870%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$1,247
- MIEBO$875
- VYZULTA$875
- XIIDRA$500
How this compares
$3,133 in reported general payments places this provider in the 85th percentile of 1,318 optometrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorometholone | 251 | $22,997 |
| RestasisCyclosporine | 13 | $21,213 |
| MieboPerfluorohexyloctane/Pf | 18 | $13,556 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $11,264 |
| LumiganBimatoprost | 16 | $10,064 |
| Prednisolone Acetate | 106 | $5,600 |
| Loteprednol Etabonate | 21 | $4,257 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,130 |
| Travoprost | 18 | $2,260 |
| Brimonidine Tartrate | 16 | $1,989 |
| Latanoprost | 62 | $330 |
| Timolol Maleate | 48 | $270 |
| Dorzolamide Hcl | 17 | $211 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 32 | $199 |
| Ofloxacin | 14 | $155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $105 | $35,40740 claims |
| Bausch & Lomb Americas Inc.Miebo | $982 | $13,55618 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $69 | $4,25721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,318 optometrist providers in Indiana.
Other optometrist in Indianapolis
- Damon DierkerIndianapolis$707K
- Rhonda RobinsonIndianapolis$205K
- Brenda WahlIndianapolis$38K
- Peter KoernerIndianapolis$11K
- Jessica HultsIndianapolis$10K
- Branden ShafferIndianapolis$9K
- Scott AllisonIndianapolis$8K
- Alma NoreikaIndianapolis$7K
- Scott HastyIndianapolis$7K
- Diana FisherIndianapolis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.